| Literature DB >> 31794579 |
Richard Njouom1, Chavely Gwladys Monamele1, Hermann Landry Munshili Njifon1, Sebastien Kenmoe1, Mohamadou Ripa Njankouo1.
Abstract
Since the recent emergence of several subtypes of influenza viruses with pandemic potentials, there has been growing interest on the control of this infection worldwide. This study aimed to describe the 10 years of influenza activity in Cameroon between January 2009 and December 2018. Respiratory samples were collected from sentinel sites responsible for influenza surveillance in Cameroon and analyzed for the presence of influenza. Globally, 9 of the 10 administrative regions of the country were represented with at least 1 year of data. A total of 11816 respiratory samples were collected and influenza virus detection rate was 24.0%. The most represented age group was the 0-1 years representing more than 40% of the collected samples and possessing the lowest proportion of influenza cases (16.2%). Meanwhile higher proportions of influenza positive cases was found in the 2-4, 5-14 and 15-49 years age group at ≥29%. Among outpatients, the frequency of influenza virus was 24.8% while in hospitalized patients, 18.7% of samples were positive for influenza virus. We noted year-round circulation of influenza virus in Cameroon with 2 peaks in activity: a major peak in the months of September to December and a minor peak in the months of March to July. Antigenic characterization of influenza isolates showed 37.5% (6/16) vaccine match between the predominant Cameroon strains and the Northern hemisphere vaccine strains with majority of vaccine match observed in influenza B/Victoria subtype (4/6; 66.7%). Data collected from this surveillance system is essential to add to global information on the spread of influenza.Entities:
Year: 2019 PMID: 31794579 PMCID: PMC6890244 DOI: 10.1371/journal.pone.0225793
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Temporal and regional distribution of sentinel sites in Cameroon.
| Region | Site name | Distribution over years | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | ||
| Centre | CMA de Nkomo | + | + | + | + | + | + | + | + | ||
| CASS de Nkolndongo | + | + | + | + | + | + | + | + | + | + | |
| CMS Ambassade de France | + | + | + | + | + | + | + | + | + | + | |
| CSI d’Etoudi | + | + | + | + | + | + | + | + | + | + | |
| Centre Hospitalier d’Essos | + | + | + | + | + | + | + | + | + | + | |
| Hôpital Jamot de Yaoundé* | + | + | |||||||||
| North | Hôpital Provincial de Garoua | + | |||||||||
| CSI de Koléré | + | + | + | + | + | + | |||||
| CSI de Ourokanadi | + | + | + | ||||||||
| CSI de Poumpouré | + | + | + | ||||||||
| CSI de Souari | + | + | + | ||||||||
| CSI de Kotta Liddiri | + | + | + | + | + | ||||||
| Hôpital de Foulbéré | + | + | + | + | + | ||||||
| CSI de Roumde Adjia | + | + | + | + | + | ||||||
| Garoua Regional Hospital | + | + | |||||||||
| West | CMA Koukouet Maloum | + | |||||||||
| CMA Djeleng | + | + | |||||||||
| CSI de Bandjoun | + | + | + | + | + | + | + | + | + | + | |
| CSI de Kueka (Foumban) | + | + | + | + | + | + | + | + | + | + | |
| Littoral | Hôpital Catholique Barcelone | + | |||||||||
| Hôpital de District New Bell Pédiatrie | + | + | + | ||||||||
| Hôpital d’Albert le Grand | + | + | + | + | + | + | + | + | + | + | |
| Hôpital Catholique de Log Pom | + | + | + | + | + | + | + | ||||
| Far North | Hôpital de Kolofata | + | + | ||||||||
| Adamawa | CSI de Boumdjéré | + | + | + | |||||||
| CSI de Marza | + | + | + | ||||||||
| CSI de Sabongari | + | + | + | ||||||||
| Hopital Protestant de Ngaoundéré | + | + | + | ||||||||
| South | Ebolowa Regional Hospital | + | + | + | + | ||||||
| South West | Mount Mary Hospital Buea | + | + | + | + | ||||||
| North West | Polyclinic St Blaise Bamenda | + | + | + | + | ||||||
*SARI sites; In brackets () are the number of sites represented in each region or year
Fig 1Presentation of sentinel sites by region.
Triangles represent ILI sites while stars represent SARI sites.
Reference viruses for haemagglutination inhibition assay.
| Virus Type | Reference strains | Year |
|---|---|---|
| A(H3N2) | A/Wisconsin/67/2005 | 2009 |
| A/Brisbane/10/2007 | 2009 | |
| A/Uruguay/716/2007 | 2009 | |
| A/Finland/9/2008 | 2009 | |
| A/Johannesburg/15/2008 | 2009 | |
| A/Hong Kong/1952/2009 | 2009 | |
| A/Hong Kong/1985/2009 | 2009 | |
| A/Perth/16/2009 | 2013–2014 | |
| A/Stockholm/18/2011 | 2013 | |
| A/Iowa/19/2010 | 2013 | |
| A/Victoria/361/2011 | 2013–2014 | |
| A/Athens/112/2012 | 2013 | |
| A/Texas/50/2012 | 2013–2015 | |
| A/Samara/73/2013 | 2013–2015 | |
| A/Serbia/NS210/2013 | 2013 | |
| A/Hong Kong/146/2013 | 2013–2015 | |
| NIB-85 (A/Almaty/2958/2013) | 2013 | |
| A/South Africa/4655/2013 | 2014 | |
| A/Stockholm/6/2014 | 2014–2015 | |
| A/Norway/466/2014 | 2014 | |
| A/Netherlands/525/2014 | 2015 | |
| A/Hong Kong/5738/2014 | 2015 | |
| A/Hong Kong/4801/2014 | 2015 | |
| A/Switzerland/9715293/2013 | 2014–2015 | |
| A/Georgia/532/2015 | 2015 | |
| A(H1N1)pdm09 | A/California/4/2009 | 2010 |
| A/California/7/2009 | 2010, 2011, 2013, 2015, 2018 | |
| A/England/195/2009 | 2010 | |
| A/Auckland/3/2009 | 2010 | |
| A/Bayern/69/2009 | 2010, 2011, 2013, 2015, 2018 | |
| A/Lviv/N6/2009 | 2010, 2011, 2013, 2015, 2018 | |
| A/Hong Kong/2212/2010 | 2010 | |
| A/Christchurch/16/2010 | 2010, 2011, 2013, 2015 | |
| A/Hong Kong/3934/2011 | 2011, 2013 | |
| A/Astrakhan/1/2011 | 2011, 2013, 2015, 2018 | |
| A/St. Petersburg/27/2011 | 2011, 2013, 2015, 2018 | |
| A/St. Petersburg/100/2011 | 2011, 2013, 2015 | |
| A/Hong Kong/5659/2012 | 2013, 2015, 2018 | |
| A/South Africa/3626/2013 | 2013, 2015, 2018 | |
| A/Slovenia/2903/2015 | 2015, 2018 | |
| A/Michigan/45/2015 | 2017 | |
| A/Israel/Q-504/2015 | 2018 | |
| A/Paris/1447/2017 | 2018 | |
| B/Victoria | B/Shandong/7/97 | 2010 |
| B/Malaysia/2506/2004 | 2010–2011, 2014, 2016 | |
| B/Victoria/304/2006 | 2010 | |
| B/England/393/2008 | 2010–2011 | |
| B/Brisbane/60/2008 | 2010–2011, 2014, 2016 | |
| B/Paris/1762/2008 | 2010–2011, 2014 | |
| B/Hong Kong/514/2009 | 2010–2011, 2014,2016 | |
| B/Odessa/3886/2010 | 2010–2011, 2014 | |
| B/Malta/636714/2011 | 2014, 2016 | |
| B/Johannesburg/3964/2012 | 2014, 2016 | |
| B/Formosa/V2367/2012 | 2014, 2016 | |
| B/South Australia/81/2012 | 2014, 2016 | |
| B/Ireland/3154/2016 | 2016 | |
| B/Nordrhein-Westfalen/1/2016 | 2016 | |
| B/Yamagata | B/Florida/4/2006 | 2013, 2016 |
| B/Brisbane/3/2007 | 2013, 2016 | |
| B/Wisconsin/1/2010 | 2013, 2016, 2018 | |
| B/Stockholm/12/2011 | 2013, 2016, 2018 | |
| B/Estonia/55669/2011 | 2013, 2016, 2018 | |
| B/Novosibirsk/1/2012 | 2013 | |
| B/Hong Kong/3577/2012 | 2013 | |
| B/Massachusetts/02/2012 | 2013, 2016, 2018 | |
| B/Phuket/3073/2013 | 2016, 2018 | |
| B/Hong Kong/3417/2014 | 2016 | |
| B/Mauritius/1791/2017 | 2018 |
Proportion of influenza positive cases between 2009 and 2018.
| No. tested | Influenza virus positive | OR | P-value | Distribution of influenza virus type/ subtype | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A(H3N2) | A(H1N1)pdm09 | A(H1N1) | A untyped | B | A and B | |||||
| 0–1 | 4884 | 791 (16.2) | Ref | Ref | 288 (36.4) | 157 (19.8) | 0 | 53 (6.7) | 281 (35.5) | 12 (1.5) |
| 2–4 | 2823 | 818 (29.0) | 2.11 | <0.001 | 301 (36.8) | 196 (24.0) | 1 (0.1) | 62 (7.6) | 251 (30.7) | 7 (0.9) |
| 5–14 | 1464 | 467 (31.9) | 2.42 | <0.001 | 155 (33.2) | 84 (18.0) | 2 (0.4) | 22 (4.7) | 200 (42.8) | 4 (0.9) |
| 15–49 | 1443 | 431 (29.9) | 2.20 | <0.001 | 190 (44.1) | 85 (19.7) | 1 (0.2) | 20 (4.6) | 131 (30.4) | 4 (0.9) |
| 50–64 | 202 | 53 (26.2) | 1.84 | <0.001 | 29 (54.7) | 6 (11.3) | 0 | 3 (5.7) | 14 (26.4) | 1 (1.9) |
| ≥ 65 | 101 | 27 (26.7) | 1.88 | 0.005 | 16 (59.3) | 1 (3.7) | 0 | 1 (3.7) | 7 (25.9) | 2 (7.4) |
| No data | 899 | 248 (27.6) | 100 (40.3) | 61 (24.6) | 0 | 20 (8.1) | 59 (23.8) | 8 (3.2) | ||
| Male | 5459 | 1261 (23.1) | 0.94 | 0.191 | 474 (37.6) | 261 (20.7) | 3 (0.2) | 78 (6.2) | 427 (33.9) | 18 (1.4) |
| Female | 5392 | 1303 (24.2) | Ref | Ref | 492 (37.8) | 266 (20.4) | 1 (0.1) | 82 (6.3) | 450 (34.5) | 12 (0.9) |
| No data | 965 | 271 (28.1) | 113 (41.7) | 63 (23.2) | 0 | 21 (7.7) | 66 (24.4) | 8 (3.0) | ||
| ILI | 10193 | 2531 (24.8) | 1.43 | <0.001 | 960 (37.9) | 501 (19.8) | 3 (0.1) | 153 (6.0) | 878 (34.7) | 36 (1.4) |
| SARI | 1547 | 290 (18.7) | Ref | Ref | 110 (37.9) | 86 (29.7) | 0 | 27 (9.3) | 65 (22.4) | 2 (0.7) |
| No data | 76 | 14 (18.4) | 9 (64.3) | 3 (21.4) | 1 (7.1) | 1 (7.1) | 0 | 0 | ||
| 0–5 | 9230 | 2343 (25.4) | Ref | Ref | 912 (38.9) | 489 (20.9) | 3 (0.1) | 143 (6.1) | 766 (32.7) | 30 (1.3) |
| 6–10 | 1186 | 234 (19.7) | 0.72 | <0.001 | 74 (31.6) | 55 (23.5) | 0 | 12 (5.1) | 86 (36.8) | 7 (3.0) |
| >10 | 465 | 70 (15.1) | 0.52 | <0.001 | 26 (37.1) | 12 (17.1) | 0 | 7 (10.0) | 24 (34.3) | 1 (1.4) |
| No data | 935 | 188 (20.1) | 67 (35.6) | 34 (18.1) | 1 (0.5) | 19 (10.1) | 67 (35.6) | 0 | ||
| Centre | 6474 | 1604 (24.8) | Ref | Ref | 678 (42.3) | 305 (19.0) | 2 (0.1) | 106 (6.6) | 493 (30.7) | 20 (1.2) |
| Adamawa | 459 | 70 (15.3) | 0.55 | <0.001 | 25 (35.7) | 25 (35.7) | 0 | 3 (4.3) | 17 (24.3) | 0 |
| Far North | 60 | 13 (21.7) | 0.84 | 0.579 | 11 (84.6) | 2 (15.4) | 0 | 0 | 0 | 0 |
| Littoral | 1173 | 359 (30.6) | 1.34 | <0.001 | 128 (35.7) | 66 (18.4) | 0 | 19 (5.3) | 137 (38.2) | 9 (2.5) |
| North | 1566 | 386 (24.6) | 0.99 | 0.917 | 68 (17.6) | 111 (28.8) | 0 | 28 (7.3) | 176 (45.6) | 3 (0.8) |
| North West | 332 | 73 (22.0) | 0.86 | 0.251 | 24 (32.9) | 11 (15.1) | 0 | 12 (16.4) | 25 (34.2) | 1 (1.4) |
| South | 216 | 60 (27.8) | 1.17 | 0.316 | 19 (31.7) | 23 (38.3) | 0 | 2 (3.3) | 15 (25.0) | 1 (1.7) |
| South West | 316 | 70 (22.2) | 0.86 | 0.291 | 37 (52.9) | 11 (15.7) | 0 | 2 (2.9) | 17 (24.3) | 3 (4.3) |
| West | 1220 | 200 (16.4) | 0.60 | <0.001 | 89 (44.5) | 36 (18.0) | 2 (1.0) | 9 (4.5) | 63 (31.5) | 1 (0.5) |
Fig 2Distribution and trends in influenza virus positivity rate from 2009–2018.
The primary y-axis represents the frequency of each subtype; the secondary y-axis represents the percentage positive for influenza and the x-axis represents the months.
Fig 3Influenza virus positivity rate among ILI and SARI cases.
Total represents the overall percentage positive for influenza; %ILI represents the percentage positive for influenza among patients with ILI; %SARI represents the percentage positive for influenza among patients with SARI.
Antigenic characterization of influenza strains in Cameroon and comparison to vaccine strains.
| Year | Virus Type | Predominant Cameroon strains | n/N | % | Northern Hemisphere vaccine strain | Vacine Match |
|---|---|---|---|---|---|---|
| 2009 | A(H3N2) | A/Uruguay/716/2007 (A/Brisbane/10/2007-like) | 25/25 | 100 | A/Brisbane/10/2007 | Yes |
| 2010 | A(H1N1)pdm09 | A/Auckland/3/2009 (A/California/7/2009-like) | 73/90 | 81.1 | / | / |
| B/Victoria | B/Hong Kong/514/2009 (B/Brisbane/60/2008-like) | 93/102 | 91.2 | B/Brisbane/60/2008 | Yes | |
| 2011 | A(H1N1)pdm09 | A/St. Petersburg/100/2011 | 20/22 | 90.9 | A/California/7/2009 | No |
| B/Victoria | B/Paris/1762/2008 (B/Brisbane/60/2008-like) | 25/26 | 96.2 | B/Brisbane/60/2008 | Yes | |
| 2013 | A(H3N2) | A/Samara/73/2013 | 12/16 | 75 | A/Victoria/361/2011 | No |
| A(H1N1)pdm09 | A/St. Petersburg/100/2011 | 27/27 | 100 | A/California/7/2009 | No | |
| B/Yamagata | B/Hong Kong/3577/2012 | 31/33 | 93.9 | B/Wisconsin/1/2010 | No | |
| 2014 | A(H3N2) | A/Stockholm/6/2014 | 11/11 | 100 | A/Victoria/361/2011 | No |
| B/Victoria | B/Hong Kong/514/2009 (B/Brisbane/60/2008-like) | 7/11 | 63.3 | B/Brisbane/60/2008 | Yes | |
| 2015 | A(H3N2) | A/Stockholm/6/2014 | 5/5 | 100 | A/Texas/50/2012 | No |
| A(H1N1)pdm09 | A/St. Petersburg/100/2011 | 21/21 | 100 | A/California/7/2009 | No | |
| 2016 | B/Yamagata | B/Hong Kong/3417/2014 | 5/6 | 83.3 | B/Phuket/3073/2013 | No |
| B/Victoria | B/Ireland/3154/2016 (B/Brisbane/60/2008-like) | 24/25 | 96 | B/Brisbane/60/2008 | Yes | |
| 2017 | A(H1N1)pdm09 | A/Slovenia/2903/2015 | 18/18 | 100 | A/Michigan/45/2015 | No |
| 2018 | B/Yamagata | B/Phuket/3073/2013 | 19/19 | 100 | B/Phuket/3073/2013 | Yes |
**quadivalent vaccine strain
* match between predominant Cameroon strains and Northern hemisphere vaccin strain
(/) = not applicable
n/N represents the proportion of Cameroon strains showing highest titers for the reference strains